CAMBRIDGE, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapy company focused on driving innovation to transform outcomes for cancer patients, today presented ...
- Lunit to present three abstracts about its AI biomarker platform Lunit SCOPE IO, also to be demonstrated during the event in booth #423 - One immunotherapy combination study adds significant ...
– exoSTING™ monotherapy suppressed tumor growth and improved overall survival in a preclinical model of leptomeningeal disease, an aggressive metastasis of cancer to the central nervous system – – ...
Oncorus Inc. offered initial safety, tolerability and immune activation and clinical response data from its ongoing phase I trial with ONCR-177 at the Society for Immunotherapy of Cancer (SITC) ...
It’s been a decade since the first checkpoint inhibitors were approved, but the problem of low response rates remains in many forms of cancer. Highlight Therapeutics SL, of Valencia, Spain, hopes to ...
Markets Insider and Business Insider Editorial Teams were not involved in the creation of this post. Fate Therapeutics NewsMORE Related Stocks Indices Commodities Currencies Stocks ...
Markets Insider and Business Insider Editorial Teams were not involved in the creation of this post. Codiak BioSciences NewsMORE Related Stocks Indices Commodities Currencies Stocks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results